Cambridge-based Nuclera, a biotechnology company enabling rapid protein expression and purification screening through its benchtop protein platform, has appointed William J Kullback as a non-executive director.

Kullback has financial experience from large life science tool manufacturers and more than 30 years’ experience as a chief financial officer, focusing on financial and manufacturing operations, mergers and acquisitions, and public markets across multiple publicly traded companies.

Since August 2023, he has been chief financial officer at Telesis Bio, which specialises in automated synthesis technology for therapeutic discovery. He was previously chief financial officer at BioLegend, a provider of antibodies and life science reagents, where he helped manage the company’s $5.25 billion sale to NYSE listed Revvity (previously PerkinElmer).

Kullback also negotiated and closed acquisitions and investments while chief financial officer at medical device company, Lombard Medical, prior to its acquisition by MicroPort Scientific Corporation. He has also held senior financial positions at a range of medical device and life science tools businesses.

Dr Michael Chen, co-founder and chief executive of Nuclera, said: “[Kullback’s] distinguished career and financial expertise will be instrumental as we push forward with our growth strategy in line with our commercial goals. Bill’s experience will be invaluable to Nuclera as we scale to address current challenges in protein production by bringing eProtein Discovery to even more researchers.”

Kullback commented: “Nuclera’s eProtein Discovery has the potential to transform drug discovery workflows. The company is at an exciting stage as it expands globally and I am looking forward to working with the team to support the company’s growth and drive success at this pivotal stage in Nuclera’s development.”